Somapacitan + Norditropin®
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
SGA, Turner Syndrome, Noonan Syndrome, ISS
Conditions
SGA, Turner Syndrome, Noonan Syndrome, ISS
Trial Timeline
Aug 10, 2022 → Oct 29, 2027
NCT ID
NCT05330325About Somapacitan + Norditropin®
Somapacitan + Norditropin® is a phase 3 stage product being developed by Novo Nordisk for SGA, Turner Syndrome, Noonan Syndrome, ISS. The current trial status is active. This product is registered under clinical trial identifier NCT05330325. Target conditions include SGA, Turner Syndrome, Noonan Syndrome, ISS.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05330325 | Phase 3 | Active |
| NCT04970654 | Phase 3 | Completed |
| NCT03878446 | Phase 2 | Active |
| NCT03811535 | Phase 3 | Completed |
Competing Products
10 competing products in SGA, Turner Syndrome, Noonan Syndrome, ISS
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Somatropin | Eli Lilly | Phase 3 | 77 |
| Humatrope | Eli Lilly | Approved | 85 |
| 17 beta estradiol | Eli Lilly | Phase 3 | 77 |
| Somatropin + Ethinyl estradiol + Medroxyprogesterone acetate | Eli Lilly | Phase 3 | 77 |
| r-hGH | Merck | Approved | 85 |
| estradiol | Novo Nordisk | Approved | 84 |
| Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch | Novo Nordisk | Phase 1 | 32 |
| somatotropin | Pfizer | Pre-clinical | 22 |
| Lonapegsomatropin + Somatropin | Ascendis Pharma | Phase 2 | 49 |
| Somatropin (rDNA origin) | Ipsen | Phase 3 | 74 |